Ifinatamab deruxtecan by Daiichi Sankyo for Neuroendocrine Tumors: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.

Generative AI falls short in accurately identifying global health policies

Generative AI tools enhance data collection in health policy analysis but show notable inaccuracies, especially in African and Eastern Mediterranean regions.

December 17, 2024

Trump 2.0 could see a rise in biopharmaceutical M&A deals – Pharmaceutical Technology

The second Trump administration is expected to focus on domestic M&A. Credit Brandon Bell / Getty Images. Trump’s return to the White House will mean

December 5, 2024

New synthetic antibiotic found to be more effective than established drugs against ‘superbugs’

A new synthetic antibiotic developed by University of Liverpool researchers is shown to be more effective than established drugs against ‘superbugs’ such as MRSA, a

January 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.